Ibuprofen Medisorb 200 mg 20 capsules

Ibuprofen Medisorb is used for headaches, migraines, toothaches, painful menstruation, neuralgia, back pain, muscle and rheumatic pain; for febrile conditions associated with influenza and colds.

For oral use. For short-term use only.
Adults and children over 12 years: take 1 capsule (200 mg) orally, without chewing, up to 3-4 times a day. The capsule should be taken with water. The interval between doses should be 6-8 hours.
To achieve a faster therapeutic effect in adults, the single dose may be increased to 2 capsules (400 mg) up to 3 times a day.
The maximum daily dose is 1200 mg.
The maximum daily dose for children aged 12-17 years is 1000 mg.
If symptoms persist or worsen after taking the medication for 2-3 days, treatment should be discontinued and a doctor should be consulted.

Per 1 capsule:
active ingredient: ibuprofen - 200 mg;
excipients: croscarmellose sodium; talc; magnesium stearate; aerosil (colloidal silicon dioxide)
composition of hard gelatin capsules No. 1: gelatin, titanium dioxide, iron oxide yellow, indigo carmine

Hard gelatin capsules No. 1, white in color, with green caps, containing a powder that is white or white with a yellowish tint.

• Hypersensitivity to ibuprofen and/or any of the components of the product;

• Complete or incomplete combination of bronchial asthma, recurrent nasal and paranasal sinus polyps, and intolerance to acetylsalicylic acid and/or other NSAIDs (including in history);

• Erosive-ulcerative lesions of the gastrointestinal tract (including peptic ulcer disease of the stomach and duodenum, Crohn's disease, ulcerative colitis) or active phase of ulcerative bleeding or in history (two or more confirmed episodes of peptic ulcer disease or ulcerative bleeding);

• History of gastrointestinal bleeding or perforation of an ulcer provoked by NSAID use;

• Severe heart failure (class IV according to NYHA - New York Heart Association classification);

• Severe liver failure or active liver disease;

• Severe renal failure (creatinine clearance

It is recommended to take the medication for the shortest possible duration and at the minimum effective dose necessary to alleviate symptoms.
During prolonged treatment, monitoring of peripheral blood parameters and the functional state of the liver and kidneys is necessary.
If symptoms of gastropathy appear, careful monitoring is indicated, including esophagogastroduodenoscopy, complete blood count (hemoglobin determination), and stool analysis for occult blood.
If 17-ketosteroids need to be determined, the medication should be discontinued 48 hours prior to the study.
During treatment, the intake of ethanol is not recommended.
Patients with renal insufficiency should consult a physician before using the medication, as there is a risk of worsening kidney function.
Patients with hypertension, including a history of it and/or chronic heart failure, should consult a physician before using the medication, as it may cause fluid retention, increased blood pressure, and edema.
Patients with uncontrolled arterial hypertension, congestive heart failure class II-III according to NYHA, ischemic heart disease, peripheral artery diseases, and/or cerebrovascular diseases should be prescribed ibuprofen only after a careful assessment of the benefit-risk ratio, while avoiding the use of high doses of ibuprofen (> 2400 mg/day).
The use of NSAIDs in patients with chickenpox may be associated with an increased risk of severe purulent complications of infectious-inflammatory skin and subcutaneous tissue diseases (e.g., necrotizing fasciitis). Therefore, it is recommended to avoid the use of the medication in chickenpox.
Information for women planning pregnancy: these medications inhibit cyclooxygenase and prostaglandin synthesis, affecting ovulation and disrupting female reproductive function (reversible after discontinuation of treatment).
Effect on the ability to drive vehicles and operate machinery:
Patients experiencing dizziness, drowsiness, lethargy, or visual disturbances while taking ibuprofen should avoid driving vehicles or operating machinery.

The risk of side effects can be minimized by taking the medication for a short course, at the minimum effective dose necessary to alleviate symptoms.
Side effects are predominantly dose-dependent.
The following adverse reactions have been observed with short-term use of ibuprofen at doses not exceeding 1200 mg/day (6 capsules). The appearance of other side effects may occur when treating chronic conditions and with prolonged use.
The frequency of adverse reactions has been assessed based on the following criteria: very common (≥1/10); common (≥1/100 to

In children, overdose symptoms may occur after taking a dose exceeding 400 mg/kg of body weight. In adults, the dose-dependent effect of overdose is less pronounced.
The half-life of the drug in cases of overdose is 1.5-3 hours.
Symptoms: nausea, vomiting, pain in the epigastric region or, less commonly, diarrhea, tinnitus, headache, and gastrointestinal bleeding. In more severe cases, manifestations from the central nervous system may occur: drowsiness, rarely - agitation, seizures, disorientation, coma. In cases of severe poisoning, metabolic acidosis and increased prothrombin time, renal failure, liver tissue damage, decreased blood pressure, respiratory depression, and cyanosis may develop. In patients with bronchial asthma, exacerbation of the condition may occur.
Treatment: symptomatic, with mandatory maintenance of airway patency, monitoring of ECG and vital signs until the patient's condition normalizes. Oral administration of activated charcoal and gastric lavage is recommended within 1 hour after ingestion of a potentially toxic dose of ibuprofen. If ibuprofen has already been absorbed, alkaline drinks may be prescribed to facilitate the excretion of the acidic derivative of ibuprofen by the kidneys, forced diuresis. Frequent or prolonged seizures should be controlled by intravenous administration of diazepam or lorazepam. In case of worsening bronchial asthma, the use of bronchodilators is recommended.

Avoid simultaneous use of ibuprofen with the following medications:

• acetylsalicylic acid: except for low doses of acetylsalicylic acid (no more than 75 mg per day) prescribed by a doctor, as concurrent use may increase the risk of side effects. When used together, ibuprofen reduces the anti-inflammatory and antiplatelet effects of acetylsalicylic acid (there may be an increased incidence of acute coronary insufficiency in patients receiving low doses of acetylsalicylic acid as an antiplatelet agent after starting ibuprofen);

• other NSAIDs, including selective COX-2 inhibitors: simultaneous use of two or more NSAIDs should be avoided due to the potential increased risk of side effects.

Use with caution in combination with the following medications:

• anticoagulants and thrombolytics: NSAIDs may enhance the effect of anticoagulants, particularly warfarin and thrombolytics;

• antihypertensive agents (angiotensin-converting enzyme (ACE) inhibitors and angiotensin II antagonists) and diuretics: NSAIDs may reduce the effectiveness of these drug classes. Diuretics and ACE inhibitors may increase the nephrotoxicity of NSAIDs;

• glucocorticoids: increased risk of gastrointestinal ulcers and gastrointestinal bleeding.

• antiplatelets and SSRIs: increased risk of gastrointestinal bleeding;

• cardiac glycosides: concurrent use of NSAIDs and cardiac glycosides may worsen heart failure, decrease glomerular filtration rate, and increase plasma concentrations of cardiac glycosides;

• lithium: there is evidence of a potential increase in lithium plasma concentrations with NSAID use;

• methotrexate: there is evidence of a potential increase in methotrexate plasma concentrations with NSAID use;

• cyclosporine: increased risk of nephrotoxicity with concurrent use of NSAIDs and cyclosporine;

• mifepristone: NSAIDs should not be started earlier than 8-12 days after taking mifepristone, as NSAIDs may reduce the effectiveness of mifepristone;

• tacrolimus: concurrent use of NSAIDs and tacrolimus may increase the risk of nephrotoxicity;

• zidovudine: concurrent use of NSAIDs and zidovudine may lead to increased hematotoxicity. There is evidence of an increased risk of hemarthrosis and hematomas in HIV-positive patients with hemophilia receiving combined treatment with zidovudine and ibuprofen;

• quinolone antibiotics: patients receiving combined treatment with NSAIDs and quinolone antibiotics may have an increased risk of seizures;

• cefamandole, cefoperazone, cefotetan, valproic acid, plikamycine: increased incidence of hypoprothrombinemia;

• medications that block tubular secretion: reduced elimination and increased plasma concentration of ibuprofen;

• inducers of microsomal oxidation (phenytoin, ethanol, barbiturates, rifampicin, phenylbutazone, tricyclic antidepressants): increased production of hydroxylated active metabolites, increased risk of severe intoxications;

• inhibitors of microsomal oxidation: reduced risk of hepatotoxic effects;

• oral hypoglycemic agents and insulin, sulfonylurea derivatives: enhanced effect;

• antacids and cholestyramine: reduced absorption;

• caffeine: enhanced analgesic effect.

The mechanism of action of ibuprofen, a propionic acid derivative from the group of non-steroidal anti-inflammatory drugs (NSAIDs), is based on the inhibition of prostaglandin (PG) synthesis - mediators of pain, inflammation, and hyperthermic response. It non-selectively blocks cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2), thereby inhibiting PG synthesis. It provides rapid targeted action against pain (analgesic), antipyretic, and anti-inflammatory effects. Additionally, ibuprofen reversibly inhibits platelet aggregation.

Absorption
Absorption is high; it is rapidly and almost completely absorbed from the gastrointestinal tract (GIT). Taking the medication with food may increase the time to reach maximum concentration (Tmax). After taking 2 capsules of the medication on an empty stomach, ibuprofen is detected in the plasma within 10 minutes, and the maximum concentration (Cmax) of ibuprofen in the plasma is reached within 30-40 minutes.

Distribution
Binding to plasma proteins is over 90%. It slowly penetrates the joint cavity, accumulating in the synovial fluid, creating higher concentrations there than in the plasma.

Metabolism
It undergoes metabolism in the liver. After absorption, about 60% of the pharmacologically inactive R-form of ibuprofen is slowly transformed into the active S-form.

Excretion
The half-life (T1/2) of ibuprofen is 2 hours. It is excreted by the kidneys (in unchanged form, no more than 1%) and, to a lesser extent, with bile.

Elderly patients
No significant differences in the pharmacokinetic profile of the medication were found in elderly patients compared to younger patients.
In limited studies, ibuprofen was detected in breast milk at very low concentrations.

Ibuprofen Medisorb 200 mg is a medicinal product. It provides rapid targeted action against pain (analgesic), antipyretic, and anti-inflammatory effects. It is used in the following cases: headache; migraine; toothache; painful menstruation; neuralgia; back pain; muscle and rheumatic pain; febrile conditions in influenza and colds. Please read the instructions carefully before taking the medication.
For oral use. For short-term use only. Adults and children over 12 years: orally, after meals, 1 capsule (200 mg) 3-4 times a day. The capsule should be taken with water. The interval between doses should be 6–8 hours.
To achieve a rapid therapeutic effect in adults, the dose may be increased to 2 capsules (400 mg) up to 3 times a day.
Do not take more than 6 capsules in 24 hours.
The maximum daily dose is 1200 mg (6 capsules).
The maximum daily dose for children aged 12–17 years is 1000 mg. It is recommended to consult a doctor before use.